Researchers have found evidence that non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen, aspirin, and naproxen, may exert a protective effect against the risk of Alzheimer’s disease. Results of their epidemiological, multiple-study analysis of nearly 16,000 patients are being presented at the American Academy of Neurology Annual Meeting in Honolulu, March 29-April 5, 2003.
In a breakthrough study, scientists have found that common painkillers such as ibuprofen and naproxen may actually dissolve the brain lesions — or amyloid plaques — that are one of the definitive hallmarks of Alzheimer’s disease. The findings are reported in the March 31 issue of Neuroscience. Principal investigator Jorge R. Barrio, professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, has used FDDNP, a new chemical marker developed in his laboratory at UCLA, to visually zero in on the brain lesions present in Alzheimer’s disease. He discovered that common over-the-counter pain medications — known as non-steroidal anti-inflammatory drugs — bind to amyloid plaques, and may help dissolve existing plaques and prevent the formation of new ones.
A new study has found that consumption of moderate amounts of green or white tea might provide a protection against colon tumors about as well as a prescription drug, sulindac, that has been shown to be effective for that purpose. The research was just published in the journal Carcinogenesis by scientists from the Linus Pauling Institute at Oregon State University, in studies funded by the National Cancer Institute. It may suggest some optional approaches to cancer prevention or therapy, especially for people who have trouble with the side effects that can be associated with regular use of non-steroidal anti-inflammatory drugs, or NSAIDs, such as sulindac or aspirin.
Anti-inflammatory drugs used to treat arthritis may also benefit people with heart disease by improving blood vessel flexibility and reducing inflammation, according to a small study in today’s rapid track report from Circulation: Journal of the American Heart Association. “Increasing evidence indicates that atherosclerosis is an inflammatory disease,” says senior author Frank Ruschitzka, M.D., of the department of cardiology at University Hospital in Z?rich, Switzerland. “Thus, anti-inflammatory agents used to treat arthritis, such as COX-2 inhibitors, may not only reduce inflammation in the joints, but could possibly have that same anti-inflammatory benefit in the vessel wall. This study is the first to show that relationship.”
Researchers have found that selective COX-2 inhibitors ? a class of medications widely prescribed for painful inflammatory conditions such as osteoarthritis and rheumatoid arthritis – interfere with the healing process after a bone fracture or cementless joint implant surgery. Their findings suggest that patients who regularly take COX-2 inhibitors should switch to a different medication, such as acetaminophen or codeine derivatives, following a bone fracture or cementless implant.